PRESS RELEASE published on 01/23/2025 at 22:05, 10 months 12 days ago Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress Abivax announces presentation of seven abstracts for Obefazimod in ulcerative colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress Abivax Obefazimod Ulcerative Colitis Clinical Trials ECCO
BRIEF published on 01/09/2025 at 17:40, 10 months 26 days ago Abivax Reaches Key Enrollment Milestone in Phase 3 ABTECT Trial Abivax Obefazimod Ulcerative Colitis Phase 3 Trial Clinical Results
PRESS RELEASE published on 01/09/2025 at 17:35, 10 months 26 days ago Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Abivax achieves key milestone in Phase 3 ABTECT trial enrollment with 82% of target participants enrolled for evaluating obefazimod in ulcerative colitis, aiming for NDA submission by H2 2026 Abivax Obefazimod Ulcerative Colitis Phase 3 ABTECT Trial
BRIEF published on 12/23/2024 at 22:10, 11 months 12 days ago Abivax Announces Board Resignation Abivax Obefazimod Board Resignation Truffle Capital Philippe Pouletty
PRESS RELEASE published on 12/23/2024 at 22:05, 11 months 12 days ago Abivax Announces a Change to the Composition of its Board of Directors Abivax announces a change in its Board of Directors composition as Dr. Philippe Pouletty resigns due to new appointment. The company expresses gratitude for his contributions Board Of Directors Resignation Abivax Therapeutics Dr. Philippe Pouletty
BRIEF published on 12/18/2024 at 18:05, 11 months 17 days ago ABIVAX: Share capital and voting rights as of November 30, 2024 Euronext Paris Share Capital Voting Rights Abivax Investment
BRIEF published on 11/27/2024 at 18:05, 1 year ago ABIVAX: Update of Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights Abivax Financial Transparency
BRIEF published on 11/19/2024 at 22:35, 1 year ago Abivax Launches ATM Program on Nasdaq Common Shares Biotechnology Funding Nasdaq ATM Program
PRESS RELEASE published on 11/19/2024 at 22:30, 1 year ago Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
BRIEF published on 11/14/2024 at 22:06, 1 year ago Abivax Releases Q3 2024 Financial Results Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
Published on 12/05/2025 at 16:00, 33 minutes ago SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 48 minutes ago Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 58 minutes ago XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:00, 1 hour 33 minutes ago Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 16:25, 8 minutes ago 4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 23 minutes ago Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 33 minutes ago EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 33 minutes ago EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 16:00, 33 minutes ago Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 15:10, 1 hour 22 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 7 hours 48 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 22 hours 33 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 22 hours 48 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 22 hours 49 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
